Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren

OBJECTIVES: A double-blind, randomised, placebo-controlled clinical trial was performed to validate the hypothesis that the use of lozenges containing Lactobacillus brevis CD2 (Inersan®, CD Investments srl) may reduce plaque pH, salivary mutans streptococci (ms) and bleeding on probing, during a 6-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Campus, Guglielmo, Cocco, Fabio, Carta, Giovanna, Cagetti, Maria Grazia, Simark-Mattson, Charlotte, Strohmenger, Laura, Lingström, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936134/
https://www.ncbi.nlm.nih.gov/pubmed/23644602
http://dx.doi.org/10.1007/s00784-013-0980-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936134/
https://www.ncbi.nlm.nih.gov/pubmed/23644602
http://dx.doi.org/10.1007/s00784-013-0980-9

Ejemplares similares